News

Did you miss any of our print issues this year? Don’t worry, they are still available online.

Curacle plans to finalize its development strategy, including phase 2b and 3 trials, through a Type C meeting with the US FDA in February of 2025.

The publication is entitled, “Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies.”

In the statement, the board calls attention to a proposal by a committee in the US House of Representatives that would shrink the National Institutes of Health’s (NIH) from 27 institutes into 15 institutes.

The European Commission will assess the marketing authorisation for Eydenzelt (reference product Eylea)

Espansione Group is known for photobiomodulation (PBM) technology – the Light Modulation Low-level Light Therapy (LLLT) along with the Intense Pulsed Light (IPL) technology.

The company is advancing its Phase I/II trial and exploring accelerated approval pathways in the US and Europe.

USC is leading a research team aiming to better understand retinitis pigmentosa and inform future treatments.

QUASAR is a global, double-masked, active-controlled phase 3 trial evaluating the efficacy and safety of EYLEA HD, compared to EYLEA, in patients with RVO, including those with central, branch and hemiretinal vein occlusions.

In the LIGHTHOUSE study, Atsena Therapeutics is evaluating ATSN-201 gene therapy for X-linked retinoschisis, leveraging AAV.SPR capsid for central retina transduction without foveal detachment risks.

The PFS is approved for treatment of neovascular age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion.

A global survey explores the impact of geographic atrophy (GA) on quality of life, revealing similar challenges for individuals with unilateral and bilateral GA.

Phenocell and Amarna Therapeutics were awarded the grant by Eureka’s Eurostars initiative, co-funded by the European Union.

Within 4 months of AEYE-DS's deployment, diabetic retinopathy screening adherence increased from 29 percent to 49 percent.

Tenpoint Therapeutics and Visus Therapeutics have merged to focus on aging-related ocular conditions, with key products including BRIMOCHOL PF for presbyopia and therapies for cataracts and geographic atrophy.

A study investigating the impact of socioeconomic status on open globe injury (OGI) found that lower SES, measured by the Social Vulnerability Index and Distressed Communities Index, correlates with younger age, non-accidental injuries, and poorer visual outcomes in OGI patients.

Kaczmarek has a notable background of executive leadership and operational expertise in the gene therapy manufacturing industry.

This interview comes at the Children's Hospital Los Angeles team celebrates its 100th retinal gene therapy procedure.

The aim of this program is to help advance junior clinical research scientists in their professional endeavors to cure retinal degenerative disease.

This study was published online in the journal Aging Cell and reveals how DNA damage compromises the retina’s function and accelerates vision loss.

The researchers conducted a retrospective study to assess serum inflammatory biomarkers in patients with different subtypes of diabetic macular edema (DME).

Roche, Ainnova, and Salud 360 signed this alliance to improve access to vision screening in patients with uncontrolled diabetes.

Nona Biosciences has partnered with Kodiak Sciences to develop multi-target antibodies for ophthalmic diseases. Utilizing Nona's Harbour Mice platform, the collaboration aims to accelerate antibody discovery, focusing on innovative therapies for retinal and other eye conditions.

ACELYRIN will not make any additional internal investment in developing izokibep.

EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in development.

Recognition may translate into policy changes and behavioral improvement.

The annual meeting brought announcements and insights from companies in the retina care space.